壊死性筋膜炎治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR4045)
◆英語タイトル:Global Necrotizing Fasciitis Drug Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR4045
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:91
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥499,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥748,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、壊死性筋膜炎治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(アミノグリコシド系抗生物質、メトロニダゾール系抗生物質、クリンダマイシン系抗生物質、フルオロコナゾール系抗生物質、その他)、用途別市場規模(病院薬局、オンライン薬局、ドラッグストア)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・壊死性筋膜炎治療薬の市場動向
・企業の競争状況、市場シェア
・壊死性筋膜炎治療薬の種類別市場規模(アミノグリコシド系抗生物質、メトロニダゾール系抗生物質、クリンダマイシン系抗生物質、フルオロコナゾール系抗生物質、その他)
・壊死性筋膜炎治療薬の用途別市場規模(病院薬局、オンライン薬局、ドラッグストア)
・壊死性筋膜炎治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・壊死性筋膜炎治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・壊死性筋膜炎治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・壊死性筋膜炎治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・壊死性筋膜炎治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(GlaxoSmithKline、Pfizer、Bristol-Myers Squibb、Merck、Abbott、Teva、WOCKHARDT、Atox Bio、Basilea Pharmaceutica、MELINTA THERAPEUTICS)
・結論
【レポートの概要】

Necrotizing Fasciitis is rare but serious bacterial infection commonly known as flesh eating disease which affects the tissue beneath the skin and surrounding organs and muscles.

Market Analysis and Insights: Global Necrotizing Fasciitis Drug Market
The global Necrotizing Fasciitis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Necrotizing Fasciitis Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Necrotizing Fasciitis Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Necrotizing Fasciitis Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Necrotizing Fasciitis Drug market.

Global Necrotizing Fasciitis Drug Scope and Market Size
Necrotizing Fasciitis Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Necrotizing Fasciitis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Aminoglycoside
Metronidazole
Clindamycin
Fluoroconazoles
Others

Segment by Application
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Pfizer
Bristol-Myers Squibb
Merck
Abbott
Teva
WOCKHARDT
Atox Bio
Basilea Pharmaceutica

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Necrotizing Fasciitis Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Aminoglycoside
1.2.3 Metronidazole
1.2.4 Clindamycin
1.2.5 Fluoroconazoles
1.2.6 Others
1.3 Market by Application
1.3.1 Global Necrotizing Fasciitis Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Online Pharnacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Necrotizing Fasciitis Drug Market Perspective (2016-2027)
2.2 Necrotizing Fasciitis Drug Growth Trends by Regions
2.2.1 Necrotizing Fasciitis Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Necrotizing Fasciitis Drug Historic Market Share by Regions (2016-2021)
2.2.3 Necrotizing Fasciitis Drug Forecasted Market Size by Regions (2022-2027)
2.3 Necrotizing Fasciitis Drug Industry Dynamic
2.3.1 Necrotizing Fasciitis Drug Market Trends
2.3.2 Necrotizing Fasciitis Drug Market Drivers
2.3.3 Necrotizing Fasciitis Drug Market Challenges
2.3.4 Necrotizing Fasciitis Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Necrotizing Fasciitis Drug Players by Revenue
3.1.1 Global Top Necrotizing Fasciitis Drug Players by Revenue (2016-2021)
3.1.2 Global Necrotizing Fasciitis Drug Revenue Market Share by Players (2016-2021)
3.2 Global Necrotizing Fasciitis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Necrotizing Fasciitis Drug Revenue
3.4 Global Necrotizing Fasciitis Drug Market Concentration Ratio
3.4.1 Global Necrotizing Fasciitis Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Necrotizing Fasciitis Drug Revenue in 2020
3.5 Necrotizing Fasciitis Drug Key Players Head office and Area Served
3.6 Key Players Necrotizing Fasciitis Drug Product Solution and Service
3.7 Date of Enter into Necrotizing Fasciitis Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Necrotizing Fasciitis Drug Breakdown Data by Type
4.1 Global Necrotizing Fasciitis Drug Historic Market Size by Type (2016-2021)
4.2 Global Necrotizing Fasciitis Drug Forecasted Market Size by Type (2022-2027)

5 Necrotizing Fasciitis Drug Breakdown Data by Application
5.1 Global Necrotizing Fasciitis Drug Historic Market Size by Application (2016-2021)
5.2 Global Necrotizing Fasciitis Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Necrotizing Fasciitis Drug Market Size (2016-2027)
6.2 North America Necrotizing Fasciitis Drug Market Size by Type
6.2.1 North America Necrotizing Fasciitis Drug Market Size by Type (2016-2021)
6.2.2 North America Necrotizing Fasciitis Drug Market Size by Type (2022-2027)
6.2.3 North America Necrotizing Fasciitis Drug Market Size by Type (2016-2027)
6.3 North America Necrotizing Fasciitis Drug Market Size by Application
6.3.1 North America Necrotizing Fasciitis Drug Market Size by Application (2016-2021)
6.3.2 North America Necrotizing Fasciitis Drug Market Size by Application (2022-2027)
6.3.3 North America Necrotizing Fasciitis Drug Market Size by Application (2016-2027)
6.4 North America Necrotizing Fasciitis Drug Market Size by Country
6.4.1 North America Necrotizing Fasciitis Drug Market Size by Country (2016-2021)
6.4.2 North America Necrotizing Fasciitis Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Necrotizing Fasciitis Drug Market Size (2016-2027)
7.2 Europe Necrotizing Fasciitis Drug Market Size by Type
7.2.1 Europe Necrotizing Fasciitis Drug Market Size by Type (2016-2021)
7.2.2 Europe Necrotizing Fasciitis Drug Market Size by Type (2022-2027)
7.2.3 Europe Necrotizing Fasciitis Drug Market Size by Type (2016-2027)
7.3 Europe Necrotizing Fasciitis Drug Market Size by Application
7.3.1 Europe Necrotizing Fasciitis Drug Market Size by Application (2016-2021)
7.3.2 Europe Necrotizing Fasciitis Drug Market Size by Application (2022-2027)
7.3.3 Europe Necrotizing Fasciitis Drug Market Size by Application (2016-2027)
7.4 Europe Necrotizing Fasciitis Drug Market Size by Country
7.4.1 Europe Necrotizing Fasciitis Drug Market Size by Country (2016-2021)
7.4.2 Europe Necrotizing Fasciitis Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Necrotizing Fasciitis Drug Market Size (2016-2027)
8.2 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Type
8.2.1 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Application
8.3.1 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Region
8.4.1 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Necrotizing Fasciitis Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Necrotizing Fasciitis Drug Market Size (2016-2027)
9.2 Latin America Necrotizing Fasciitis Drug Market Size by Type
9.2.1 Latin America Necrotizing Fasciitis Drug Market Size by Type (2016-2021)
9.2.2 Latin America Necrotizing Fasciitis Drug Market Size by Type (2022-2027)
9.2.3 Latin America Necrotizing Fasciitis Drug Market Size by Type (2016-2027)
9.3 Latin America Necrotizing Fasciitis Drug Market Size by Application
9.3.1 Latin America Necrotizing Fasciitis Drug Market Size by Application (2016-2021)
9.3.2 Latin America Necrotizing Fasciitis Drug Market Size by Application (2022-2027)
9.3.3 Latin America Necrotizing Fasciitis Drug Market Size by Application (2016-2027)
9.4 Latin America Necrotizing Fasciitis Drug Market Size by Country
9.4.1 Latin America Necrotizing Fasciitis Drug Market Size by Country (2016-2021)
9.4.2 Latin America Necrotizing Fasciitis Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Necrotizing Fasciitis Drug Market Size (2016-2027)
10.2 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Type
10.2.1 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Application
10.3.1 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Country
10.4.1 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Necrotizing Fasciitis Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Necrotizing Fasciitis Drug Introduction
11.1.4 GlaxoSmithKline Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Necrotizing Fasciitis Drug Introduction
11.2.4 Pfizer Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Necrotizing Fasciitis Drug Introduction
11.3.4 Bristol-Myers Squibb Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Necrotizing Fasciitis Drug Introduction
11.4.4 Merck Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Abbott
11.5.1 Abbott Company Details
11.5.2 Abbott Business Overview
11.5.3 Abbott Necrotizing Fasciitis Drug Introduction
11.5.4 Abbott Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.5.5 Abbott Recent Development
11.6 Teva
11.6.1 Teva Company Details
11.6.2 Teva Business Overview
11.6.3 Teva Necrotizing Fasciitis Drug Introduction
11.6.4 Teva Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.6.5 Teva Recent Development
11.7 WOCKHARDT
11.7.1 WOCKHARDT Company Details
11.7.2 WOCKHARDT Business Overview
11.7.3 WOCKHARDT Necrotizing Fasciitis Drug Introduction
11.7.4 WOCKHARDT Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.7.5 WOCKHARDT Recent Development
11.8 Atox Bio
11.8.1 Atox Bio Company Details
11.8.2 Atox Bio Business Overview
11.8.3 Atox Bio Necrotizing Fasciitis Drug Introduction
11.8.4 Atox Bio Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.8.5 Atox Bio Recent Development
11.9 Basilea Pharmaceutica
11.9.1 Basilea Pharmaceutica Company Details
11.9.2 Basilea Pharmaceutica Business Overview
11.9.3 Basilea Pharmaceutica Necrotizing Fasciitis Drug Introduction
11.9.4 Basilea Pharmaceutica Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.9.5 Basilea Pharmaceutica Recent Development
11.10 MELINTA THERAPEUTICS
11.10.1 MELINTA THERAPEUTICS Company Details
11.10.2 MELINTA THERAPEUTICS Business Overview
11.10.3 MELINTA THERAPEUTICS Necrotizing Fasciitis Drug Introduction
11.10.4 MELINTA THERAPEUTICS Revenue in Necrotizing Fasciitis Drug Business (2016-2021)
11.10.5 MELINTA THERAPEUTICS Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 壊死性筋膜炎治療薬の世界市場規模・現状・予測2021年-2027年(Global Necrotizing Fasciitis Drug Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。